What Cardosal 40 Treats: Main Uses and Benefits

Cardosal 40 (Olmesartan Medoxomil) is commonly used to help manage the chronic and often asymptomatic condition of high blood pressure (hypertension) in adults and children aged 6 years and older. The primary therapeutic purpose of managing high blood pressure is to provide long-term support for general cardiovascular health, which may assist with reducing the chance of developing future serious cardiovascular issues.

---

The medication is relevant for easing this condition, which is characterized by periods of elevated arterial pressure readings, and is applied in clinical settings that involve comprehensive risk management for patients with conditions marked by increased physiological stress, such as chronic kidney disease or diabetes.

“Controlling blood pressure is a fundamental strategy used to support organs during periods of increased physiological stress linked to circulatory strain.”

It is commonly used to help with essential hypertension in adults and is considered relevant for managing blood pressure in high-risk groups, including pediatric patients (6 years and older). By managing this high-pressure environment, Cardosal 40 assists with managing symptoms linked to organ-specific functional stress, which contributes to easing the overall symptom load. It may be used as a sole agent or may be part of symptomatic management alongside other medications in scenarios where additional management of discomfort is required to support the management of symptoms related to heightened physiological activity.

---

Quick Fact: Relief for Elevated Arterial Pressure

Who Must Not Use (Contraindications)

Cardosal 40 (Olmesartan Medoxomil) is absolutely contraindicated for several groups based on regulatory documents. Use is prohibited for patients in the second and third trimesters of pregnancy and for children below 1 year of age. The medicine must not be used by individuals with known hypersensitivity to the active substance, or by those with biliary obstruction. Furthermore, co-administration with Aliskiren is contraindicated in patients with diabetes mellitus or specific renal impairment.

Age and Condition Limitations

The medicine is approved for use in adults and pediatric patients aged 6 to 17 years with hypertension. Use is not established for children aged 1 to 5 years. Regulatory bodies state that use is not recommended in patients with severe renal impairment or severe hepatic impairment due to limited clinical experience. For moderate hepatic impairment, a specific maximum dose restriction applies. Additionally, a choice must be made by nursing mothers to discontinue either breastfeeding or the drug, as use is generally not recommended.

Cardosal 40 Interactions with other medicines and products

It is crucial to inform your doctor or pharmacist about all prescription, over-the-counter, and herbal medicines you are currently taking or plan to take before starting treatment with Cardosal 40 (which contains the active ingredient Valsartan). Combining Cardosal 40 with certain other products can alter their effects or increase the risk of side effects.

Significant Drug-Drug Interactions

Particular caution is required when co-administering Cardosal 40 with the following classes of medicines:

• Potassium-Sparing Diuretics and Potassium Supplements: Concomitant use with drugs like spironolactone, amiloride, or potassium salts increases the risk of hyperkalemia (high potassium levels), which can be serious.
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Medications such as ibuprofen or naproxen can reduce the blood-pressure-lowering effect of Cardosal 40. In patients who are elderly, volume-depleted, or have impaired kidney function, this combination may also increase the risk of worsening renal function.
• Other Angiotensin II Receptor Blockers (ARBs) or Angiotensin-Converting Enzyme (ACE) Inhibitors: Dual blockade of the renin-angiotensin system, for instance, by combining Cardosal 40 with an ACE inhibitor like enalapril, is generally not recommended due to an increased risk of hypotension, hyperkalemia, and kidney problems.
• Lithium: Monitoring of serum lithium levels is essential, as Cardosal 40 can increase the concentration and toxicity of lithium.

Always consult a healthcare professional to assess potential interactions.

Cardosal 40, which contains olmesartan medoxomil, functions as a prodrug that is rapidly hydrolyzed to its active metabolite, olmesartan, during gastrointestinal absorption. Olmesartan's primary biological targets are the angiotensin II type 1 ( AT1) receptors located on cell surfaces, particularly in vascular smooth muscle, the adrenal gland, and renal tissue.

The interaction type is a selective, competitive antagonist. Olmesartan binds with high affinity to the AT1 receptor, thereby preventing the binding and subsequent signaling cascade initiated by the endogenous ligand, angiotensin II. By blocking this receptor, the drug inhibits the intracellular pathway normally mediated by angiotensin II, which includes G-protein-coupled receptor activation and downstream increases in inositol trisphosphate ( IP3) and intracellular calcium ( Ca^2+) levels.

This antagonistic action results in a downstream cascade that inhibits two major physiological responses: vasoconstriction of the peripheral arterioles and the release of aldosterone from the adrenal cortex. The resultant system-level physiological consequence is a reduction in total peripheral vascular resistance due to vasodilation, and an increase in the renal excretion of sodium and water due to reduced aldosterone activity.

How to Use Cardosal 40

Cardosal 40 (Olmesartan Medoxomil) is an orally administered medication available in film-coated tablet strengths of 5 mg, 20 mg, and 40 mg. The medicine is designed to be taken once daily and can be administered with or without food. To support consistent dosing, the tablet should be taken at approximately the same time each day.

For administration, the film-coated tablet must be swallowed whole with an adequate amount of fluid and must not be crushed or chewed. For children unable to swallow the tablet, an extemporaneously compounded oral suspension may be prepared following specific guidelines outlined in the prescribing information.

Dosing and Adjustment Protocol

The standardized adult starting dose is 20 mg once daily. Dosage adjustment should only take place after an assessment period of approximately two weeks, with the dose potentially increasing to the maximum recommended daily limit of 40 mg. The full therapeutic effect of any dose change is often observed after two weeks, with the maximal effect typically achieved by about eight weeks.

Specific dosage limits apply to certain groups. The maximum daily dose is restricted to 20 mg for patients with moderate renal impairment or moderate hepatic impairment. For pediatric patients aged six years and older, dosing is determined by body weight, adhering to defined maximums based on the child’s size. If a dose is missed, the next dose should be taken at the regular scheduled time without taking a double dose to compensate.

Research Evidence / Overview of Studies for Cardosal 40

1. Evidence Structure for Managing High Blood Pressure (Essential Hypertension)

The scientific understanding of Cardosal 40 (Olmesartan Medoxomil) in adults is built upon core research, including Randomized Controlled Trials (RCTs). These short-term trials led to the medication’s regulatory assessment. Research examined key outcomes related to physiological strain, specifically focusing on the change in measurements of systolic and diastolic blood pressure over defined time intervals. Reports from these trials describe consistent patterns observed regarding measured changes in blood pressure readings in adults.

However, the existing evidence base relies mostly on short-term follow-up durations. The change in blood pressure measurements is considered a surrogate endpoint, meaning it is a marker rather than a direct measure of long-term health. Because of this, the data for certain long-term outcomes, such as sustained cardiovascular health over many years, are not fully established by the initial, pivotal clinical trials.

2. Research for Use in Children and Adolescents (Pediatric Hypertension)

Specific clinical research has also focused on younger patients. These studies were typically Randomized, Double-Blind, Dose-Response Studies conducted in children and adolescents between the ages of 6 and 16 years. Researchers examined outcomes related to physiological strain by monitoring dose-dependent changes in blood pressure measurements in this specific population. The research describes how changes in blood pressure were measured during the defined short-term study periods.

3. Understanding Long-Term Evidence and Durability of Effect

The majority of the evidence that established the initial use of Cardosal 40 focused on short-term measurement of change. To understand the durability of the observed changes, there is a body of longer observational research that describes data collected over multiple years. Long-term outcomes are an area where the available data limit definitive conclusions, as follow-up durations were limited in many core randomized trials.

4. Research Gaps and Areas of Scientific Uncertainty

A key uncertainty is the reliance on surrogate endpoints; blood pressure measurements do not directly equate to definitive long-term cardiovascular health outcomes. Furthermore, the research reflects the specific conditions under which they were conducted, meaning data for certain groups remain insufficient when they were not the primary focus of the initial trials. Comparative evidence is lacking for certain head-to-head comparisons.

Common questions about Cardosal 40 (FAQ)

---

Q: What exactly is Cardosal 40 used for, besides the main condition?

A: Cardosal 40 is officially indicated for the treatment of hypertension (high blood pressure) in adults and pediatric patients aged 6 years and older. Regulatory documents primarily focus on this approved indication. Any questions regarding alternative uses or conditions should be addressed with a healthcare provider.

---

Q: Is Cardosal 40 considered a 'blood thinner'?

A: Cardosal 40 is classified as an Angiotensin II Receptor Blocker (ARB), which functions to relax blood vessels and lower blood pressure. The drug’s mechanism of action does not involve anti-clotting properties like anticoagulant or antiplatelet medicines (often referred to as 'blood thinners').

---

Q: Is Cardosal 40 typically used long-term or short-term?

A: Since Cardosal 40 is prescribed for the management of essential hypertension (high blood pressure), which is usually a chronic condition, treatment duration is often prolonged. Official studies monitor the drug’s long-term effect on blood pressure changes, consistent with chronic therapy.

---

Q: How quickly does Cardosal 40 start working after the first time taking it?

A: Regulatory information indicates that the active substance, olmesartan, reaches its highest concentration in the bloodstream approximately one to two hours after administration. This pharmacokinetic measurement of peak concentration is distinct from the assessment of the full, stabilized blood pressure reduction, which typically requires consistent use over several weeks.

---

Q: Is Cardosal 40 safe for older adults (seniors)?

A: Regulatory studies show that the drug's concentration in the body is similar between the elderly population (65 years and older) and younger adults. Consideration for specific factors like existing kidney or liver function is important, as noted in the official prescribing information.

---

Q: Can Cardosal 40 affect my sleep?

A: Official regulatory documents indicate that insomnia, or difficulty sleeping, has been reported as an adverse reaction in clinical trials for Cardosal 40. This information is noted in the drug's official safety profile.

---

Q: Is Cardosal 40 known to cause anxiety?

A: Official safety information includes anxiety among the psychiatric-related side effects that have been reported in clinical studies for Cardosal 40. This finding is documented in the official regulatory data.

---

Q: Are there any specific foods I should avoid while using Cardosal 40?

A: Official product warnings indicate that the use of Cardosal 40 may increase potassium levels. Therefore, combining it with high-potassium foods, potassium salt substitutes, or supplements is associated with a risk of developing high potassium (hyperkalemia).

---

Q: Does Cardosal 40 have any known interaction with alcohol?

A: Regulatory warnings state that alcohol can have an additive blood pressure-lowering effect when used alongside Cardosal 40. The official safety data indicates this may increase the risk of symptoms associated with low blood pressure, such as dizziness or fainting.

---

Q: Is the '40' in Cardosal 40 the same as the milligram strength?

A: The number 40 in Cardosal 40 refers to the 40 milligram (mg) strength of the available tablet, which is one of the strengths manufactured. This is a common pharmaceutical naming convention to indicate the dose of the active ingredient.

---

Q: Where can I find reliable research about Cardosal 40?

A: The most reliable and comprehensive source for official safety and efficacy evidence is the regulatory documentation published by government health agencies, such as the FDA Approved Label or the EMA Summary of Product Characteristics (SmPC). These documents compile the clinical data used in the approval process for the medicine.

---

Q: Does Cardosal 40 affect blood sugar levels?

A: Official reports indicate that hyperglycemia (an increase in blood sugar levels) has been listed as a reported adverse reaction of Cardosal 40 in clinical trials. This finding is noted in the drug's regulatory safety profile.

---

Q: Does Cardosal 40 have a generic version available?

A: The active ingredient in Cardosal 40, known as olmesartan medoxomil, is available in a generic formulation. Regulatory product information confirms the availability of generic versions that contain the same active compound.

---

Q: How long does Cardosal 40 stay in your system?

A: Based on pharmacokinetics data from official documents, the active form of the medicine, olmesartan, has a terminal elimination half-life of approximately 13 hours. The half-life is a scientific measure describing the time required for half of the drug to be eliminated from the bloodstream.

---

Q: Is Cardosal 40 a controlled substance?

A: No, Cardosal 40 (olmesartan medoxomil) is not classified as a controlled substance by regulatory authorities. Controlled substance designation applies to substances with potential for abuse, which is a regulatory status distinct from Angiotensin II Receptor Blockers (ARBs).

How to Store and Dispose of Cardosal 40

The storage and disposal of Cardosal 40 (Olmesartan Medoxomil) must adhere strictly to official regulatory guidelines to maintain stability and ensure safety.

---

Storage Requirements

• Tablets: Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The product must be kept protected from moisture and must not be frozen.
• Oral Suspension: The extemporaneously prepared liquid form must be refrigerated at 2 C to 8 C and has a shelf-life of up to 4 weeks (28 days).

All medicine must be kept out of the reach of children.

---

Disposal Instructions

Expired or unused Cardosal 40 must not be thrown away with household trash or disposed of via wastewater (e.g., flushed down the toilet). Any remaining oral suspension must be discarded after 4 weeks. Consult a pharmacist for proper pharmaceutical waste disposal procedures.